AEZS European approval to market MacrillenAEterna has a variety of new products in its pipeline.
Macrilen, for example, is the first and only FDA-approved oral test for the diagnosis of Adult Growth Hormone Deficiency.
AEterna received European approval to market Macrillen.
Dr. Christian Strasburger: "Clinical studies have demonstrated that macimorelin is safer and much simpler to administer than the current methods of testing for insulin-induced hypoglycemia, and is well-tolerated by patients and reliable in diagnosing the condition.”
I think AEZS is a sleeping giant.
My price target is $1.25.
AEZS
C+H on the 1M Chart perhapsI'm a novice but looking at the 1 Month chart looks like a distinct Cup and Handle forming, thoughts???
$AEZS trend reversal Based off trend lines.
AEZS recently gained compliance
Volume has been low the last few days compared to average
Earnings to be announced on March 30th
$AEZS Bullish Indicators Bullish Indicators
- Falling Wedge
- Wide RSI Divergence
- Aeterna Zentaris to Present at the H.C. Wainwright Global Life Sciences Conference March 9-10
AEZS Bullish FlagAs you can see we have a textbook Bullish flag pattern.
With positive earnings coupled with great news.
finance.yahoo.com
seekingalpha.com
The only downside is that EPS is at -0.18.
Bullish on AEZS . Stock crosses key indicators!We have been monitoring $AEZS for sometime. The stock has crossed key technical indicators. We are bullish.
We are are confident the stock will remain relatively stable now that the base of support is forming above the 200EMA. We will also look to buy the stock on weakness. Given that this is a BIOTECH that is dependant on clinical trials and FDA approval, huge swings could occur based on those outcomes.
Should the stock fall below the 200EMA and develops negative indicators, we will re-evaluate our position.
Our target price for this stock is $5.00 (fair value)
